|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000027719 |
|
Date of registration:
|
12/06/2017 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Effect of tapering methotrexate in rheumatoid arthritis patients after add-on iguratimod therapy.
|
|
Scientific title:
|
Effect of tapering methotrexate in rheumatoid arthritis patients after add-on iguratimod therapy. - Effect of tapering MTX in RA patinents after add-on IGU theraoy. |
|
Date of first enrolment:
|
2017/06/12 |
|
Target sample size:
|
100 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031756 |
|
Study type:
|
Interventional |
|
Study design:
|
Parallel Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Shuzo Yoshida |
|
Address:
|
2-7 Daigakumachi, Takatsuki city, Osaka 569-8686, Japan
|
|
Telephone:
|
+81-72-683-1221 |
|
Email:
|
in1307@osaka-med.ac.jp |
|
Affiliation:
|
Osama medical college Department of Internal Medicine (4) |
|
|
Name:
|
Shuzo Yoshida |
|
Address:
|
2-7 Daigakumachi, Takatsuki city, Osaka 569-8686, Japan
|
|
Telephone:
|
+81-72-683-1221 |
|
Email:
|
in1307@osaka-med.ac.jp |
|
Affiliation:
|
Osaka Medical College Department of Internal Medicine (4) |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: add-on another csDMARDs or bDMARDs within 8 weeks.
Age minimum:
20years-old
Age maximum:
100years-old
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
rheumatoid arthritis/remission
|
|
Intervention(s)
|
add-on iguratimod tapering MTX
continuing the treatment
|
|
Primary Outcome(s)
|
|
rate of sustaining remission after 36 weeks
|
|
Secondary Outcome(s)
|
|
ultrasound findings (power Doppler score, Grey scale score) SF-36, HAQ, dose of MTX
|
|
Source(s) of Monetary Support
|
|
Osaka Medical College
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|